Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors

ChemMedChem

Volumn 5, Issue 6, 2010, Pages 827-831

  Lv, Binhua ^a,b   Feng, Yan ^b   Dong, Jiajia ^b   Xu, Min ^b   Xu, Baihua ^a,b   Zhang, Wenbin ^b   Sheng, Zelin ^b   Welihinda, Ajith ^c   Seed, Brian ^c   Chen, Yuanwei ^a,b  

^a CHENGDU INSTITUTE OF ORGANIC CHEMISTRY   (China)

^b Egret Pharma (Shanghai) Limited   (China)

^c Theracos Inc   (United States)

Author keywords

C glycosides; Diabetes mellitus; Inhibitors; SGLT2; Spiro compounds

Indexed keywords

ANTIDIABETIC AGENT; BENZOIC ACID; DAPAGLIFLOZIN; GLUCOSIDE; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM ION; SPIRO(INDANE 1,2' PYRAN) GLUCOSIDE; SPIRO(ISOBENZOFURAN 1,2' PYRAN) GLUCOSIDE; UNCLASSIFIED DRUG;

ARTICLE; BROMINATION; CRYSTAL STRUCTURE; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; ESTERIFICATION; MOLECULAR MODEL; OXIDATION; PRIORITY JOURNAL;

ANIMALS; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; HYPOGLYCEMIC AGENTS; RATS; RATS, SPRAGUE-DAWLEY; SODIUM-GLUCOSE TRANSPORTER 1; SODIUM-GLUCOSE TRANSPORTER 2; SPIRO COMPOUNDS;

EID: 77953116362     PISSN: 18607179     EISSN: 18607187     Source Type: Journal    
DOI: 10.1002/cmdc.201000051     Document Type: Article

References (31)

1. IDF Diabetes Atlas, 3rd ed., Hoorens Printing NV, Heule, 2006.
2. National Diabetes Fact Sheet (US, 2005), Centers for Disease Control and Prevention (CDC); http://apps.nccd.cdc.gov/ddtstrs/template/ndfs-2005.pdf (Last accessed: April 6, 2010).
3. AACE Diabetes Mellitus Guidelines, Endocr. Pract. 2007, 13 (Suppl. 1), S4-S68.
4. American Diabetes Association, Diabetes Care 2007, 30 (Suppl. 1), S4- S41; DOI: 10.2337/dc07-S004.
5. Y. Kanai, W. S. Lee, G. You, D. Brown, M. A. Hediger, J. Clin. Invest. 1994, 93, 397-404.
6. L. P. van den Heuvel, K. Assink, M. Willemsen, L. Monnens, Hum. Genet. 2002, 111, 544-547.
7. E. M. Wright, Am. J. Physiol. 1998, 275, G879-882.
8. J. M. Pascual, D. Wang, B. Lecumberri, H. Yang, X. Mao, R. Yang, D. C. De Vivo, Eur. J. Endocrinol. 2004, 150, 627-633.
9. J. R. Ehrenkranz, N. G. Lewis, C. R. Kahn, J. Roth, Diabetes/Metab. Res. Rev. 2005, 21, 31-38.
10. A. Oku, K. Ueta, K. Arakawa, T. Ishihara, M. Nawano, Y. Kuronuma, M. Matsumoto, A. Saito, K. Tsujihara, M. Anai, T. Asano, Y. Kanai, H. Endou, Diabetes 1999, 48, 1794-1800.
11. K. Tsujihara, M. Hongu, K. Saito, H. Kawanishi, K. Kuriyama, M. Matsumoto, A. Oku, K. Ueta, M. Tsuda, A. Saito, J. Med. Chem. 1999, 42, 5311-5324.
12. M. Isaji, Curr. Opin. Invest. Drugs 2007, 8, 285-292.
13. W. N. Washburn, J. Med. Chem. 2009, 52, 1785-1794.
14. W. N. Washburn, Expert Opin. Ther. Pat. 2009, 19, 1485-1499.
15. B. Komoroski, N. Vachharajani, D. Boulton, D. Kornhauser, M. Geraldes, L. Li, M. Pfister, Clin. Pharmacol. Ther. 2009, 85, 520-526.
16. B. Komoroski, N. Vachharajani, Y. Feng, L. Li, D. Kornhauser, M. Pfister, Clin. Pharmacol. Ther. 2009, 85, 513-519.
17. Clinical trial: CANagliflozin Treatment and Trial Analysis-Sulfonylurea (CANTATA-SU) SGLT2 Add-on to Metformin Versus Glimepiride, 2009; details can be found here: http://clinicaltrials.gov/ct2/show/NCT00968812 (Last accessed: April 6, 2010).
18. J. Z. Gougoutas, (Bristol-Myers Squibb Co., Princeton, NJ, USA), WO 2002/083066 A2, 2002;
19. [Chem. Abstr. 2002, 137, 311199].
20. B. Lv, B. Xu, Y. Feng, K. Peng, G. Xu, J. Du, L. Zhang, W. Zhang, T. Zhang, L. Zhu, H. Ding, Z. Sheng, A. Welihinda, B. Seed, Y. Chen, Bioorg. Med. Chem. Lett. 2009, 19, 6877-6881.
21. D. Horton, W. Priebe, Carbohydr. Res. 1981, 94, 27-41.
22. P. P. Deshpande, B. A. Ellsworth, J. Singh, C. Lai, G. Crispino, M. E. Randazzo, J. Z. Gougoutas, T. W. Denzel, (Bristol-Myers Squibb Co., Princeton, NJ, USA), WO 2004/063209 A2, 2004;
23. [Chem. Abstr. 2004, 141, 89317].
24. S. Czernecki, G. Ville, J. Org. Chem. 1989, 54, 610-612.
25. Y. Chen, Y. Feng, B. Xu, B. Lv, J. Dong, B. Seed, M. J. Hadd, (Theracos, Inc., Sunnyvale, CA, USA), US 2007/0275907 A1, 2007;
26. [Chem. Abstr. 2007, 147, 542 063].
27. A. M. Gómez, C. Uriel, S. Jarosz, S. Valverde, J. C. López, Eur. J. Org. Chem. 2003, 4830-4837.
28. The published selectivity of dapagliflozin for hSGLT1/hSGLT2 is 1200- fold (see Reference [27]). However, in our assays, we observed a 132- fold selectivity for hSGLT2. See Supporting Information for further details on the experimental methods used in this report.
29. N. C. Goodwin, R. Mabon, B. A. Harrison, M. K. Shadoan, Z. Y. Almstead, Y. Xie, J. Healy, L. M. Buhring, C. M. DaCosta, J. Bardenhagen, F. Mseeh, Q. Liu, A. Nouraldeen, A. G. E. Wilson, S. D. Kimball, D. R. Powell, D. B. Rawlins, J. Med. Chem. 2009, 52, 6201-6204.
30. W. Meng, B. A. Ellsworth, A. A. Nirschl, P. J. McCann, M. Patel, R. N. Girotra, G. Wu, P. M. Sher, E. P. Morrison, S. A. Biller, R. Zahler, P. P. Deshpande, A. Pullockaran, D. L. Hagan, N. Morgan, J. R. Taylor, M. T. Obermeier, W. G. Humphreys, A. Khanna, L. Discenza, J. G. Robertson, A. Wang, S. Han, J. R. Wetterau, E. B. Janovitz, O. P. Flint, J. M. Whaley, W. N. Washburn, J. Med. Chem. 2008, 51, 1145-1149.
31. R. S. Obach, Drug Metab. Dispos. 1999, 27, 1350-1359.